The ongoing COVID-19 pandemic greatly exposed a dearth of essential medications and significant vulnerabilities in the United States medical supply chain. Phlow Corporation aims to mitigate those weaknesses and manufacture essential generic medications at its Virginia manufacturing facility.
In early 2020, little-known Phlow made a splash with an $812 million contract with the Biomedical Advanced Research and Development Authority (BARDA) to manufacture essential medications in the United States. Phlow, along with strategic partners Civica Rx, Virginia Commonwealth University’s Medicines for All Institute, and AMPAC Fine Chemicals teamed up to meet the challenge of ensuring a steady supply of these essential drugs, as outlined by the U.S. Food and Drug Administration, will be available for patients.
Image: https://biobuzz.io/